AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced two-year results from the PRESERVE pivotal trial (NCT04972097) demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of intermediate-risk prostate cancer. The data will be discus.

Business Wire • May 13, 2026

Wall Street Analysts Think AngioDynamics (ANGO) Could Surge 64.23%: Read This Before Placing a Bet

The mean of analysts' price targets for AngioDynamics (ANGO) points to a 64.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research • May 6, 2026

Wall Street Analysts Believe AngioDynamics (ANGO) Could Rally 65.75%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 65.8% in AngioDynamics (ANGO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Apr 20, 2026

AngioDynamics (ANGO) Loses 5.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for AngioDynamics (ANGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Investment Research • Apr 10, 2026

AngioDynamics (ANGO) Upgraded to Buy: Here's Why

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research • Apr 8, 2026

ANGO Stock Up in Pre-Market Post Q3 Earnings Beat, Gross Margin Down

AngioDynamics tops estimates as revenue rises and losses narrow, driven by Med Tech demand, even as gross margin slips.

Zacks Investment Research • Apr 6, 2026

AngioDynamics Growing, But With More Noise Than The Street Likes

AngioDynamics is undervalued but remains a volatile, mixed-execution med tech story requiring patient investors. The Med Tech business continues to show robust growth—AlphaVac up 47%, NanoKnife up 21%—but margins and legacy Medical Devices drag on valuation. Q4 guidance disappointed due to increased R&D, inventory build, and ongoing tariff costs, though revenue guidance was raised.

Seeking Alpha • Apr 5, 2026

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q3 2026 Earnings Call Transcript

Seeking Alpha • Apr 2, 2026

AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2026, which ended February 28, 2026. Fiscal Year 2026 Third Quarter Highlights     Quarter Ended February 28, 2026   Pro Forma* YoY Growth Net Sales   $78.

Business Wire • Apr 2, 2026

AngioDynamics (ANGO) Reports Q3 Loss, Tops Revenue Estimates

AngioDynamics (ANGO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to earnings of $0.03 per share a year ago.

Zacks Investment Research • Apr 2, 2026